IL36587A - Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions - Google Patents
Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactionsInfo
- Publication number
- IL36587A IL36587A IL36587A IL3658771A IL36587A IL 36587 A IL36587 A IL 36587A IL 36587 A IL36587 A IL 36587A IL 3658771 A IL3658771 A IL 3658771A IL 36587 A IL36587 A IL 36587A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- acid
- peripheral
- group
- compositions containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 5
- 230000001413 cellular effect Effects 0.000 title description 5
- 238000000034 method Methods 0.000 title description 3
- 238000006557 surface reaction Methods 0.000 title description 3
- 150000003222 pyridines Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000000903 blocking effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 230000002093 peripheral effect Effects 0.000 description 15
- 206010003445 Ascites Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 9
- 241001061127 Thione Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000008427 organic disulfides Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
COMPOSITIONS CONTAINING PYRIDINE DERIVATIVES AND THEIR USE IN A OF CELLULAR SURFACE REACTIONS It has been discovered that cellular surface reaction can be by bringing the coll into reactive a reagent which is capable of blocking the sulfhydryl groups of the cell It has been more that the of tumor metastasis and invasiveness in living mammal can be inhibited by administering to said mammals a eagent which is capable of preferentially reacting with peripheral sulfhydryl groups present about mammalian cells rath with those sulfhydryl groups are present within the the reagent employed is one in additi to blocking the peripheral sulfhydryl groups of the also has the effect of modifying the electric charge cell It has also been discovered various types of dithio all having the structure each represents an organic have the ability to react preferentially the peripheral sulfhydryl groups present about the those of said dithio compounds wherei the R radicals incorporate groups for as which have a negative charge under pH conditions above about have the ability to modify the electric charge cell It has previously been disclosed that in experiments homogenates of Ehrlich ascites cells were found to react with acid to an ximately that of intact It has also been disclosed that in experiments basic thione forming disulfides were found to have an effect on the carbohydrate metabolism of said cells and specifically to inhibit glycolysis and respiration while acidic disulfides and most of the have little or no It has now been discovered that cotinic aoid and their sodium salts have unusual characteristics which make them particularly well adapted to be employed in mammalian systems for the reversible blocking of peripheral cellular sulfhydryl More said compounds appear to be essentially while also having the ability to react tially with peripheral rather than with intracellular hydryl said compounds have the desired ability to modify the electric charge of the treated sell The afiresaid according to the are capable of reacting with a sulfhydryl group to a thione said compounds thus being referred to as typical reaction which takes place between acid and a peripheral group on a cell can be represented as where the reaction roduct not linked to the cell is It has also been disoovered that when treating mammaliar cells with acid or their it is possible to reversibly block or essentially of the peripheral sulfhydryl groups without altering the rate of cellular respiration and glycolysis to any Significant the blocking reaction is a reversible when said reaction occurs the body of a living mammal the blocked groups return to their original form within a relatively short period of time several as a result of conventional metabolic assuming no further amounts of the cyclic reagent are available for reaction in the The tion of a thiol of the type found in mammalian systems for as will ration of free peripheral groups at a rapid deblocking wherein glutathione is indioated by oan be illustrated as follows using cotinic acid as the reagents Repeated continuous administration of the sonicotinio acid and acid or other organic disulfide reagent to the mammal of maintain the cellular system in any desired condition of peripheral aulfhydryl group blocking without damage to the order to determine which reagents are capable of preferentially reacting with peripheral eellular an excess of the reagent can be reacted first with a mass of cells and then with a lime mass of or comminuted cells of the same When the relative amount of the product compound the thione which is formed by reaction with whole cells very substantially lower than the amount formed during reaetion with the the desired preferential attribute is This method will be described below in Example Ehrlich ascites tumor cells were harvested from to transplants in female Swiss mice and then washed free of blood in the manner described below in Example One portion of cells was then left as while the other was verted to a homogenate in which essentially no whole cells were 15 samples of the intact and of the homogenized cells were incubated for 1 hour at with 5 of buffer containing 5 of one or another of the disulfide reagents enumerated below in Table with shaking in This amount was sufficient to provide a system containing the reagents a concentration of 1 X 10 After filtration through glass paper the amount of thione produc was determined from the absorbance at the wavelength indicated the In the case of 2 2 the amount of thione product formed by reaction with whole cells wa at least as high as that formed from the homogena the higher value obtained in the case of cells being attributable to enzymatic action occurrring in inta or active Each of these values was then as in Table 1 The other two reagents gave approximately this same amount of thione product when reacted w the the amount of thione provided by these two reagents when reacted with whole cells was but 20 percent o value obtained the 2 Ti indicates that these selectively thenselves to peripheral rather than to intracellular ulfhydryl These data are expressed bel in Table 1 Reagent Cha V or r 6 r 2 In op rations conducted in the but using sodium thiod nicotinic acid and of 2 2 rather than the free the thione product values obtained are essentially the same as those reported in Table 1 2 Ehrlich ascites fluid was harvested from to transplants in female Swiss the cells were separated by pentrifugation at low then suspended in KRP buffer Ringer phosphate buffer at centrifuged The cells were then KRP buffer for several times in the presence of heparin to remove red bloo The cells were in the KRP buffer to yield X cells in 10 of buffer and then incubated for 5 minutes at in the absence and presence mol of 6 6 this being sufficient to provide the system with a 10 concentration of said A portion of the resulting mixture was then used as such in the manometric The remainder of the cells were then separated by washed twice with the buffer and then resuspended in the same buffer to form a suspensio containing approximately 150 X which was then used for manometric In said the experiments were run fo one at using the method described in detail in the Effect of Some Pyridine Derivativ on the Carbohydrate Metabolism of Ehrlich Ascites et Journal of Medicinal Chemistry except that the present tests no further heparin was employed after the initial as described The results EFFECT TREATMENT ITH 6 ACID ON RESPIRATION AND O ASCITES TUMOR CELLS Ehrlich ascites cells 4 Ehrlich ascites presence of CPDS 8 ehrlich ascites treated 7 5 with then washed The data of the above Table 2 show that of Ehrlich Ascites cells with acid at concentration of 10 followed by does not alter rates of respiration and Respiration and glycolysis of Ehrlich ascites cells in the presence of acid are also essentially When the foregoing operation is repeated using thiodipyridine as the evolution of and stantially ceases afte several thus indicating that his reagent is strongly inhibitory of cell glycolysis and respiration and thus is cell Example 3 This operation was conducted to the degree persistence of the action in the living Swiss mice which had been inoculated with ascites cells 6 days before the were each injected intraperitoneal with aqueous solution containing 6 of acid sodium this dosage being equivalent to 300 of the reagent per lcilo of body This salt had been prepared by adding the acid o an aqueous solution of sodium bicarbonate present in the amount stoichiometrically required to neutralize the acid and thus the same in the aqueous The latter was then brought to a of by addition of as before being injected into each As indicated in Table 3 a certain number of mice were sacrificed at intervals of 0 and 20 hours after the reagent was After the indicated the ascites fluid was withdrawn from animal and ccntrifuged to separate the cells then 5 with lot of recovered number of which in mou e averaged 1 2 X treated with a solution of 5μ mole of cysteine resulting product was centrifuged minutes at 800 X following which the supernatant was denatured for 5 at bears a negative charge at said physiological pH The mice forming the subject of the above experiment showed no signs of discomfort when injected with the acid in a test conducted in same but using a of the acid a gum arabic solution in buffer at the mice employed in the test exhibited drowsiness for several at the end of 4 hours after it was found that 65 percent of the peripheral about the ascites cells still remained This is attributable to the fact that injected being was taken up at a slow rate and thus was able to effect a continuing reaction with the peripheral cell groups as it was slowly converted in vivo to the soluble In still another test run as a the mice were injected with a saline of and here again the symptoms of drowsiness were thus showing that the gum arabic bove was nota causative Each of 6 healthy free of any tumor or other were injected intraperitoneally with 10 mg per day of thiodinicotinic acid sodium salt for 21 consecutive equivalent to a daily dosage of 450 mg per kilo of body The injected chemical was in the as described above in Example 3 The mice exhibited no visible of drowsiness or other ill effect during the period of the test or thereafte appetites remained good and no weight loss Ehrlich ascites tumor cells were withdrawn from one or more day ascites the cells counted and diluted with physiological saline to an appropriate centrations between about and cells per ml were The preferred concentration was about Cell suspension was injected into the brain of using a Hamilton syringe and 25 gauge needle Part of the needle was vered by polyethylene tubing so as to limit the penetration of the needle into the brain to 6 The needle was inserted into the midbrain through squamopet osal fissure The mice were divided into two groups of 24 mice Those of group A received an injection IP of 2 thiodinicotinic acid in sodium bicarbonate solution every 4 hours starting within not less than one hour and not more than 3 hours after the intracerebral and for 7 consecutive days and or 4 injections Each mouse of the second group received an injection of physiological saline solution every 4 given at the same time as the injections of group for 7 consecutive days and or 42 At the end of 7 the mice were sacrificed and their lungs excised and Two portions of about 80 milligrams of minced lung tissue from each mouse were implanted neously in the retroscapular area of a healthy on both We thus had 24 mice containing implants of lungs of group A and 24 mice containing 48 implants of lungs of group B These mice were kept without any special treatment for 30 then sacrificed and any tumors that had formed at the site of the lung implants were excised and A tumor weighing 100 or more was considered a the lung tissue from which it originated contained a The results obtained in this experiments are given of Takes Average Weight 1 of Implants Takes of Tumors Group B 67 179 Group A 17 59 Average total weight of all including those weighing less than or more than 100 These results show that 6 when administered as had the effect of decreasing the number of takes to that of untreated and of creasing the total tumor mass to that of untreated It is known that still higher doses of the 6 6 tinic acid which may lead to further are well Example 6 The experiment of Example 5 was and the following results were of Takes Average Weight of Implants Takes of Tumors Group B 64 547 Group A 15 177 Example 7 o of Takes Average Weight of Implants Takes of Tumors Group B 29 133 Group A 7 79 dithionicotinic 2 dithiobisisonico The dosage rate of employed in a practice of this invention can be varied within wide limits and still be effective for the intended In good results can be obtained by nistering the reagent in amounts calculated to maintain a 6 3 concentration in blood of to So the peripheral bonding reagents have utility in modifying and moderating various undesirable reactions involving the cell periphery such as those encountered in tumor metastasis and For an advantageous use of the 6 acid herein described consists in the administration of quate doses at the time of surgery for It is known that manipulation of a tumor during surgery causes numbers of cer cells to enter the blood stream with concomitant high danger of formation of Treatment with the reagent should be continued for an adequate period of time both fore and following surgery until the natural defenses of the organism have destroyed the remaining circulating cancer or 2 acid The reagent employed in a practice of this invention to react preferentially with peripheral groups of cells can be administered to living mammals in any desired fashion for as by injection into the blood stream or into muscle or body Oral nistration may also be The chemical can be employed per se or along with an oleaginous or other vehicle which will show down its rate of absorption into the It is also possible to use a reagent of the foregoing character which is prepared in radioactive form by incorporating one more sulfur or tritium By use of this practice the efficiency and efficacy of the ve elements are greatly enhanced inasmuch as they become insufficientOCRQuality
Claims (1)
1. t. A composition consisting essentially of a solution of a compound selected from the group consisting of 6,6'^ithiodinicetinic acid, 2,2'-dithiobisisoniootinio acid and their sodium salts in a pharmaceutically acceptable diluent, being formulated for use as an agent for blocking tumor metastasis and invasiveness. 2· A composition, as claimed in Claim 1 » vherein the diluent is a physiologically acceptable buffer solution having a pH within the range 7.2 ± 0.2» Tel-Aviv, April 7, 1971
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3487370A | 1970-05-05 | 1970-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL36587A0 IL36587A0 (en) | 1971-08-25 |
| IL36587A true IL36587A (en) | 1977-10-31 |
Family
ID=21879128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL36587A IL36587A (en) | 1970-05-05 | 1971-04-11 | Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions |
Country Status (9)
| Country | Link |
|---|---|
| BE (1) | BE766123A (en) |
| CA (1) | CA985170A (en) |
| DE (1) | DE2120995A1 (en) |
| FR (1) | FR2100631B1 (en) |
| GB (1) | GB1416018A (en) |
| IL (1) | IL36587A (en) |
| NL (1) | NL173242C (en) |
| PH (1) | PH12181A (en) |
| ZA (1) | ZA712898B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152439A (en) * | 1978-01-12 | 1979-05-01 | Davide R. Grassetti | Stimulant and antidepressant agents |
| SE8102193L (en) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND ITS USE |
| SE8102194L (en) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND PHARMACEUTICAL PREPARATION INCLUDING THIS |
| DE3508666A1 (en) * | 1985-03-12 | 1986-09-18 | Hoechst Ag, 6230 Frankfurt | HETEROCYCLIC DISULFIDES AND THEIR USE AS IMMUNO MODULATORS |
| DE69834404T2 (en) * | 1997-08-05 | 2007-04-12 | The Grassetti Family Trust, Jamestown | ANTIMUTAGENMITTEL |
| AU2002239879A1 (en) | 2001-01-10 | 2002-07-24 | Davide R. Grassetti | Method of immunomodulation using thione-forming disulfides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH69A (en) * | 1889-01-09 | Charles Humbert Fils | New luminous dial system for pocket watches, clocks, public clocks, etc. | |
| CH71A (en) * | 1888-11-15 | 1889-06-13 | Th Hunziker | Apparatus for embroidering elongated needles for hand embroidery machines |
| CH70A (en) * | 1888-11-15 | 1889-01-09 | Louis Carpano | Rounding cutters for watch wheels |
| GB582638A (en) * | 1944-07-05 | 1946-11-22 | Glaxo Lab Ltd | A new anti-bacterial pyridine derivative and salts thereof |
| FR1265863A (en) * | 1959-05-04 | 1961-07-07 | Olin Mathieson | Complex fungicides containing molybdenum used in particular in agriculture |
| FR6075M (en) * | 1965-09-20 | 1968-06-04 | ||
| GB1190268A (en) * | 1966-05-12 | 1970-04-29 | Nyegaard & Co As | Pyridine Derivatives |
| ZA703779B (en) * | 1969-06-12 | 1972-01-26 | Ici Ltd | Pesticidally active compounds and compositions containing them |
-
1971
- 1971-04-11 IL IL36587A patent/IL36587A/en unknown
- 1971-04-19 PH PH12380A patent/PH12181A/en unknown
- 1971-04-22 BE BE766123A patent/BE766123A/en not_active IP Right Cessation
- 1971-04-29 DE DE19712120995 patent/DE2120995A1/en active Pending
- 1971-05-04 ZA ZA712898A patent/ZA712898B/en unknown
- 1971-05-05 FR FR7116224A patent/FR2100631B1/fr not_active Expired
- 1971-05-05 NL NLAANVRAGE7106127,A patent/NL173242C/en not_active IP Right Cessation
- 1971-05-05 GB GB1331771*[A patent/GB1416018A/en not_active Expired
- 1971-05-05 CA CA112,199A patent/CA985170A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL173242C (en) | 1984-01-02 |
| DE2120995A1 (en) | 1971-11-18 |
| NL7106127A (en) | 1971-11-09 |
| BE766123A (en) | 1971-09-16 |
| IL36587A0 (en) | 1971-08-25 |
| GB1416018A (en) | 1975-12-03 |
| CA985170A (en) | 1976-03-09 |
| ZA712898B (en) | 1973-02-28 |
| FR2100631B1 (en) | 1975-04-18 |
| PH12181A (en) | 1978-11-21 |
| FR2100631A1 (en) | 1972-03-24 |
| NL173242B (en) | 1983-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MERRILL et al. | Clinical recognition and treatment of acute potassium intoxication | |
| Iseri et al. | Magnesium and potassium therapy in multifocal atrial tachycardia | |
| Grob et al. | Potassium movement in patients with familial periodic paralysis: relationship to the defect in muscle function | |
| KEITH et al. | Some effects of potassium salts in man | |
| Heath et al. | Quantitative aspects of iron deficiency in hypochromic anemia:(The parenteral administration of iron) | |
| Hopkins | Experimental lead poisoning in the baboon | |
| WO1993018761A1 (en) | Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders | |
| GB2081094A (en) | The use of dithiocarbamic compounds in cancer therapy | |
| IL36587A (en) | Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions | |
| Schiffrin | Relationship between the parathyroid and the gastric glands in the dog | |
| Yü et al. | A simultaneous study of glycine-N15 incorporation into uric acid and heme, and of Fe59 utilization, in a case of gout associated with polycythemia secondary to congenital heart disease | |
| Perlmutter et al. | Idiopathic hypoparathyroidism and Addison's disease | |
| US4378364A (en) | Postoperative treatment of carcinoma patients | |
| US4656178A (en) | Pharmaceutical composition possessing antiarrhythmic effect | |
| Melville et al. | General systemic effects and electrocardiographic changes following injections of digitalis glycosides into the lateral ventricle of the brain | |
| Cleghorn et al. | The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate) | |
| Berliner | The effect of calcium on the heart | |
| US2259492A (en) | Therapeutic preparation of bismuth and method of preparing same | |
| US4152439A (en) | Stimulant and antidepressant agents | |
| US2312195A (en) | Salts of dextro-ascorbic acid and method of preparing same | |
| Williamson et al. | Norepinephrine sensitivity of isolated rabbit aorta strips in solutions of varying pH and electrolyte content | |
| Sugiura et al. | The influence of inorganic salts upon tumor growth in albino rats | |
| GB2044265A (en) | Adenosine Triphosphate Metal Complexes, Processes for Their Preparation and Pharmaceutical Compositions Containing Them | |
| JOOS et al. | ELECTROCARDIOGRAPHIC CHANGES DURING REPLACEMENT TRANSFUSION: Special Reference to the Effects of Serum Electrolyte Disturbances | |
| Epstein et al. | Experimental Toxicity and Local Anesthetic Activity of Alkyl Aminoethyl Esters of Meta-Amino Alkoxy Benzoates. |